


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31199696</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2167-9436</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Monoclonal antibodies in immunodiagnosis and immunotherapy</Title>
                <ISOAbbreviation>Monoclon Antib Immunodiagn Immunother</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H<sub>2</sub>Mab-41 Exerts Antitumor Activity in a Mouse Xenograft Model of Colon Cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1089/mab.2019.0017</ELocationID>
            <Abstract>
                <AbstractText>The expression of human epidermal growth factor receptor 2 (HER2) has been reported to be overexpressed in several cancers, such as breast, lung, gastric, pancreatic, and colorectal cancers, and be associated with poor clinical outcomes. Trastuzumab, a humanized anti-HER2 antibody, provides significant survival benefits for patients with HER2-overexpressing breast cancers and gastric cancers. In this study, we developed a novel anti-HER2 monoclonal antibody (mAb), H<sub>2</sub>Mab-41 (IgG<sub>2b</sub>, kappa), and the antitumor activity of H<sub>2</sub>Mab-41 was investigated using mouse xenograft models. Caco-2 cells (human colon cancer cell line), which expresses HER2, were subcutaneously implanted into the flanks of nude mice. H<sub>2</sub>Mab-41 and control mouse IgG were injected three times into the peritoneal cavity of mice. H<sub>2</sub>Mab-41 significantly reduced tumor development of Caco-2 xenograft in comparison with the control mouse IgG on days 5, 8, 11, 15, and 19. Taken together, these results suggest that H<sub>2</sub>Mab-41 is useful for antibody therapy against HER2-expressing colon cancers.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kato</LastName>
                    <ForeName>Yukinari</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>2 New Industry Creation Hatchery Center, Tohoku University, Sendai, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ohishi</LastName>
                    <ForeName>Tomokazu</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>3 Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, Numazu-shi, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamada</LastName>
                    <ForeName>Shinji</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Itai</LastName>
                    <ForeName>Shunsuke</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>4 Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takei</LastName>
                    <ForeName>Junko</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>4 Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sano</LastName>
                    <ForeName>Masato</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakamura</LastName>
                    <ForeName>Takuro</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harada</LastName>
                    <ForeName>Hiroyuki</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>4 Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawada</LastName>
                    <ForeName>Manabu</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>3 Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, Numazu-shi, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaneko</LastName>
                    <ForeName>Mika K</ForeName>
                    <Initials>MK</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Monoclon Antib Immunodiagn Immunother</MedlineTA>
            <NlmUniqueID>101590955</NlmUniqueID>
            <ISSNLinking>2167-9436</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">HER2</Keyword>
            <Keyword MajorTopicYN="N">antitumor activity</Keyword>
            <Keyword MajorTopicYN="N">colon cancer</Keyword>
            <Keyword MajorTopicYN="N">monoclonal antibody</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31199696</ArticleId>
            <ArticleId IdType="doi">10.1089/mab.2019.0017</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

